Business Wire

REPLY

22.2.2021 10:02:09 CET | Business Wire | Press release

Share
REPLY: “Everything-as-an-interface” is The New Paradigm Resulting From Reply’s “New Interfaces, Zero Interfaces” Research

The pandemic has accelerated the trend of adopting new interfaces in both consumer and professional fields, according to Reply’s new research “New Interfaces, Zero Interfaces” , based on Reply’s Trend SONAR proprietary data-driven platform.

The research explores the development prospects of state-of-the-art interfaces that are coming to prominence in this new normal by analysing significant studies, scientific articles and patents published in the last two years, while integrating them with relevant experiences from Reply customers.

Smartphones and their operating systems have been enabling completely new experiences for almost 15 years; now 5G, high-speed connectivity, and edge computing are set to provide a further boost for user interface technologies like wearables, smart speakers, 3D spatial interfaces, multimodal and brain-computer interfaces.

“Companies will develop more personalized and emotional interactions with customers, as well as new possibilities for the analysis and visualization of information,” commented Filippo Rizzante, CTO Reply. "Looking at the impacts of the pandemic on the interfaces we use today, there are two trends that more than others we are seeing growing: a wider demand for remote healthcare, and the need to reduce touch interfaces".

Voice is the fastest growing interface, thanks to its frequent use in daily life through smart speakers and cars. It is also increasingly being used for marketing purposes, allowing popular brands to literally speak directly to consumers – a much more intimate connection than the ones offered by traditional touchpoints.

Industries like pharmaceuticals, fashion, real estate, and travel are progressively implementing extended reality technologies through mobile apps or special headsets. Extended Reality is set to greatly enhance training and workplace collaboration, offering teams much better ways of meeting and sharing ideas and thoughts in both virtual and augmented realities.

Wearables are becoming steadily more relevant in the field of daily-use interfaces. Rings, glasses, and ‘hearables’ can be connected to smart assistants to help with daily life and monitor behaviour. Combined with next-gen smartwatches, these kind of wearables could become the first full-alternative, independent, consumer-ecosystem to the smartphone.

Gaze control and eye tracking will allow people to control, communicate and interact with machines based on eye movement patterns, fixations and pupil reaction. Brain-computer interface (BCI) technology is accelerating as well. The focus is still predominantly medical and scientific, however its diffusion into other areas is increasing, blurring the lines between computing and biology.

In the mobility industry , new interfaces will have a crucial role in the safety and the security of vehicle drivers and pedestrians, using new smart technologies to improve safety and communications with other road users. New interfaces will also make cars and trucks more customisable and predictive. Moreover, autonomous driving will enable greater development in entertainment and advertising within vehicles.

Retail-related interface development is experiencing seismic shifts as well, helping shoppers enjoy the benefits of physical shopping – tactile, sensory and social – in digital virtual spaces that enable frictionless and comfortable shopping while driving customer acquisition, retention and loyalty to new heights. The use of Artificial Intelligence-based and conversational interfaces will refine customisation down to the needs of the individual customer. AI and digital technologies allow for more personalisation for customers, from inspiration to tackling sizing and fitting issues in fashion retail.

With increasing sensor integration and natural embedding into the surrounding world, interfaces will be invisibly interwoven into everyday life and work environments, turning anything into an interface, seamlessly communicating with each other and expanding human cognition and senses.

For more insights download the full research “New Interfaces, Zero Interfaces” . This new research is part of the Reply Market Research series, including the recent “From Cloud to Edge” and “Rebooting Longevity” .

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye